|
1. Fusar-Poli, P. and P. Politi, Paul Eugen Bleuler and the birth of Schizophrenia
(1908). Am J Psychiatry, 2008. 165(11): p. 1407.
2. Shaw, S.H., et al., A genome-wide search for Schizophrenia susceptibility genes.
Am J Med Genet, 1998. 81(5): p. 364-76.
3. Schmidt, M.H., Diagnostic criteria of the Diagnostic and Statistical Manual of
Mental Disorders IV. Zeitschrift Fur Kinder-Und Jugendpsychiatrie Und
Psychotherapie, 1999. 27(1): p. 77-77.
4. Higaki, T., et al., Quantification and cluster analysis of actin cytoskeletal
structures in plant cells: role of actin bundling in stomatal movement during
diurnal cycles in Arabidopsis guard cells. Plant J, 2010. 61(1): p. 156-65.
5. Kelly, D.L., Treatment considerations in women with schizophrenia. J Womens
Health (Larchmt), 2006. 15(10): p. 1132-40.
6. Russell, A.T., The clinical presentation of childhood-onset schizophrenia.
Schizophr Bull, 1994. 20(4): p. 631-46.
7. Roberson, C., Schizophrenia. Ala Nurse, 2009. 36(2): p. 6-8.
8. Sernyak, M.J., et al., Association of diabetes mellitus with use of atypical
neuroleptics in the treatment of Schizophrenia. American Journal of Psychiatry,
2002. 159(4): p. 561-566.
9. Gaebel, W., et al., Schizophrenia practice guidelines: international survey and
comparison. Br J Psychiatry, 2005. 187: p. 248-55.
10. Shirzadi, A.A. and S.N. Ghaemi, Side effects of atypical antipsychotics:
extrapyramidal symptoms and the metabolic syndrome. Harv Rev Psychiatry,
2006. 14(3): p. 152-64.
11. Stahl, S.M., Polypharmacy in schizophrenia: A fuzzy concept - Dr. Stahl replies.
Journal of Clinical Psychiatry, 2003. 64(9): p. 1132-1133.
12. Tandon, R. and M.D. Jibson, Extrapyramidal side effects of antipsychotic
treatment: scope of problem and impact on outcome. Ann Clin Psychiatry, 2002.
14(2): p. 123-9.
13. Jesic, M.P., et al., Extrapyramidal syndromes caused by antipsychotics. Med
Pregl, 2012. 65(11-12): p. 521-6.
14. Haddad, P.M., et al., Antipsychotic drugs and extrapyramidal side effects in first
episode psychosis: a systematic review of head-head comparisons. J
Psychopharmacol, 2012. 26(5 Suppl): p. 15-26.
15. Nadkarni, A., et al., Medical costs and utilization in patients with depression
treated with adjunctive atypical antipsychotic therapy. Clinicoecon Outcomes
55
Res, 2013. 5: p. 49-57.
16. Kapur, S. and D. Mamo, Half a century of antipsychotics and still a central role
for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry, 2003.
27(7): p. 1081-90.
17. Tamminga, C.A., R.W. Buchanan, and J.M. Gold, The role of negative symptoms
and cognitive dysfunction in schizophrenia outcome. Int Clin Psychopharmacol,
1998. 13 Suppl 3: p. S21-6.
18. Tandon, R. and U. Halbreich, The second-generation 'atypical' antipsychotics:
similar improved efficacy but different neuroendocrine side effects.
Psychoneuroendocrinology, 2003. 28 Suppl 1: p. 1-7.
19. Ucok, A. and W. Gaebel, Side effects of atypical antipsychotics: a brief overview.
World Psychiatry, 2008. 7(1): p. 58-62.
20. Meyer, J.M. and C.E. Koro, The effects of antipsychotic therapy on serum lipids:
a comprehensive review. Schizophr Res, 2004. 70(1): p. 1-17.
21. Nasrallah, H.A. and J.W. Newcomer, Atypical antipsychotics and metabolic
dysregulation: evaluating the risk/benefit equation and improving the standard
of care. J Clin Psychopharmacol, 2004. 24(5 Suppl 1): p. S7-14.
22. Wu, R.R., et al., Effects of typical and atypical antipsychotics on glucose-insulin
homeostasis and lipid metabolism in first-episode schizophrenia.
Psychopharmacology (Berl), 2006. 186(4): p. 572-8.
23. Meyer, J., C.E. Koro, and G.J. L'Italien, The metabolic syndrome and
schizophrenia: a review. Int Rev Psychiatry, 2005. 17(3): p. 173-80.
24. Henderson, D.C., Atypical antipsychotic-induced diabetes mellitus: how strong is
the evidence? CNS Drugs, 2002. 16(2): p. 77-89.
25. Cohen, D., Atypical antipsychotics and new onset diabetes mellitus. An overview
of the literature. Pharmacopsychiatry, 2004. 37(1): p. 1-11.
26. Newcomer, J.W., Second-generation (atypical) antipsychotics and metabolic
effects: a comprehensive literature review. CNS Drugs, 2005. 19 Suppl 1: p. 1-
93.
27. Schneider, L.S., K.S. Dagerman, and P. Insel, Risk of death with atypical
antipsychotic drug treatment for dementia: meta-analysis of randomized
placebo-controlled trials. JAMA, 2005. 294(15): p. 1934-43.
28. Cooper, E., Online drug information resources: free alternatives. Med Ref Serv
Q, 2008. 27(1): p. 97-103.
29. Johnson, C.A., et al., Clinical practice guidelines for chronic kidney disease in
adults: Part I. Definition, disease stages, evaluation, treatment, and risk factors.
Am Fam Physician, 2004. 70(5): p. 869-76.
30. National Kidney, F., K/DOQI clinical practice guidelines for chronic kidney
56
disease: evaluation, classification, and stratification. Am J Kidney Dis, 2002.
39(2 Suppl 1): p. S1-266.
31. Klatsky, A.L., et al., Alcohol consumption and blood pressure Kaiser-Permanente
Multiphasic Health Examination data. N Engl J Med, 1977. 296(21): p. 1194-
200.
32. MacMahon, S.W. and R.N. Norton, Alcohol and hypertension: implications for
prevention and treatment. Ann Intern Med, 1986. 105(1): p. 124-6.
33. Marmot, M. and E. Brunner, Alcohol and cardiovascular disease: the status of
the U shaped curve. BMJ, 1991. 303(6802): p. 565-8.
34. Thomas, N. and R. Bryar, An evaluation of a self-management package for
people with diabetes at risk of chronic kidney disease. Prim Health Care Res Dev,
2013: p. 1-11.
35. Sakraida, T.J. and M.V. Robinson, Mental health and relational self-management
experiences of patients with type 2 diabetes and stage 3 chronic kidney disease.
Issues Ment Health Nurs, 2012. 33(11): p. 786-96.
36. Assogba, G.F., et al., Prevalence, screening and treatment of chronic kidney
disease in people with type 2 diabetes in France: the ENTRED surveys (2001 and
2007). Diabetes Metab, 2012. 38(6): p. 558-66.
37. Jurkovitz, C.T., et al., Association between lack of health insurance and risk of
death and ESRD: results from the Kidney Early Evaluation Program (KEEP). Am J
Kidney Dis, 2013. 61(4 Suppl 2): p. S24-32.
38. Mahfoud, F., D. Linz, and M. Bohm, [Heart and kidneys. Renal denervation as
therapy for hypertension]. Herz, 2013. 38(1): p. 67-75; quiz 76-8.
39. Yano, Y. and G.L. Bakris, Recognition and management of masked hypertension:
A review and novel approach. J Am Soc Hypertens, 2013. 7(3): p. 244-52.
40. Chang, T.I., et al., Risk factors for ESRD in individuals with preserved estimated
GFR with and without albuminuria: results from the Kidney Early Evaluation
Program (KEEP). Am J Kidney Dis, 2013. 61(4 Suppl 2): p. S4-11.
41. Thomas, R., A. Kanso, and J.R. Sedor, Chronic kidney disease and its
complications. Prim Care, 2008. 35(2): p. 329-44, vii.
42. Snively, C.S. and C. Gutierrez, Chronic kidney disease: prevention and treatment
of common complications. Am Fam Physician, 2004. 70(10): p. 1921-8.
43. Flores, J.C., et al., [Clinical guidelines on identification, management and
complications of chronic kidney disease]. Rev Med Chil, 2009. 137(1): p. 137-77.
44. Sera, N., et al., The association between chronic kidney disease and
cardiovascular disease risk factors in atomic bomb survivors. Radiat Res, 2013.
179(1): p. 46-52.
45. McClellan, W.M., et al., Chronic kidney disease is often unrecognized among
57
patients with coronary heart disease: The REGARDS Cohort Study. Am J Nephrol,
2009. 29(1): p. 10-7.
46. Polonsky, T.S. and G.L. Bakris, Chronic kidney disease: a coronary heart disease
equivalent? Lancet, 2012. 380(9844): p. 783-5.
47. Athyros, V.G., et al., Stage of chronic kidney disease and severity of coronary
heart disease manifestation. Expert Opin Pharmacother, 2012. 13(4): p. 457-60.
48. Ramkumar, N., et al., Association of obesity with inflammation in chronic kidney
disease: a cross-sectional study. J Ren Nutr, 2004. 14(4): p. 201-7.
49. Hall, J.E., et al., Is obesity a major cause of chronic kidney disease? Adv Ren
Replace Ther, 2004. 11(1): p. 41-54.
50. Stengel, B., et al., Lifestyle factors, obesity and the risk of chronic kidney disease.
Epidemiology, 2003. 14(4): p. 479-87.
51. Kramer, H., Obesity and chronic kidney disease. Contrib NepORol, 2006. 151: p.
1-18.
52. Gooch, K., et al., NSAID use and progression of chronic kidney disease. Am J
Med, 2007. 120(3): p. 280 e1-7.
53. Steele, M.R., V. Belostotsky, and K.K. Lau, The dangers of substance abuse in
adolescents with chronic kidney disease: a review of the literature. CANNT J,
2012. 22(1): p. 15-22; quiz 23-4.
54. Di Biagio, A., et al., Risk factors for chronic kidney disease among human
immunodeficiency virus-infected patients: A European case control study. Clin
Nephrol, 2011. 75(6): p. 518-23.
55. Vupputuri, S., et al., History of kidney stones as a possible risk factor for chronic
kidney disease. Ann Epidemiol, 2004. 14(3): p. 222-8.
56. Hsu, Y.H., et al., Association of betel nut chewing with chronic kidney disease: a
retrospective 7-year study in Taiwan. Nephrology (Carlton), 2011. 16(8): p. 751-
7.
57. Freedman, R., Schizophrenia. N Engl J Med, 2003. 349(18): p. 1738-49.
58. Chien, I.C., et al., Prevalence and incidence of schizophrenia among national
health insurance enrollees in Taiwan, 1996-2001. Psychiatry Clin Neurosci, 2004.
58(6): p. 611-8.
59. Tsai, K.Y., et al., The incidence and relative risk of stroke in patients with
schizophrenia: a five-year follow-up study. Schizophr Res, 2012. 138(1): p. 41-7.
60. Bresee, L.C., et al., Diabetes, cardiovascular disease, and health care use in
people with and without schizophrenia. Eur Psychiatry, 2011. 26(5): p. 327-32.
61. Kelly, D.L., et al., Cardiovascular disease mortality in patients with chronic
schizophrenia treated with clozapine: a retrospective cohort study. J Clin
Psychiatry, 2010. 71(3): p. 304-11.
58
62. Dobrin, I., et al., [Cardiovascular risk of haloperidol vs. atypical anti-psychotic
drugs in schizophrenia treatment]. Rev Med Chir Soc Med Nat Iasi, 2010.
114(3): p. 658-61.
63. Ferreira, L., et al., A case-control study of cardiovascular risk factors and
cardiovascular risk among patients with schizophrenia in a country in the low
cardiovascular risk region of Europe. Rev Port Cardiol, 2010. 29(10): p. 1481-93.
64. Bobes, J., et al., Healthy lifestyle habits and 10-year cardiovascular risk in
schizophrenia spectrum disorders: an analysis of the impact of smoking tobacco
in the CLAMORS schizophrenia cohort. Schizophr Res, 2010. 119(1-3): p. 101-9.
65. Bresee, L.C., et al., Prevalence of cardiovascular risk factors and disease in
people with schizophrenia: a population-based study. SchizopOR Res, 2010.
117(1): p. 75-82.
66. Lin, H.C., et al., Maternal schizophrenia and pregnancy outcome: does the use of
antipsychotics make a difference? Schizophr Res, 2010. 116(1): p. 55-60.
67. Tormoehlen, K. and M. Lessick, Schizophrenia in women: implications for
pregnancy and postpartum. Nurs Womens Health, 2010. 14(6): p. 482-94; quiz
495.
68. Chien, I.C., et al., Prevalence of diabetes in patients with schizophrenia in
Taiwan: a population-based National Health Insurance study. Schizophr Res,
2009. 111(1-3): p. 17-22.
69. Tabata, H., et al., Characteristics of diabetes mellitus in schizophrenic patients. J
Med Assoc Thai, 1987. 70 Suppl 2: p. 90-3.
70. Mukherjee, S., et al., Diabetes mellitus in schizophrenic patients. Compr
Psychiatry, 1996. 37(1): p. 68-73.
71. Dixon, L., et al., Prevalence and correlates of diabetes in national schizophrenia
samples. Schizophr Bull, 2000. 26(4): p. 903-12.
72. Rouillon, F. and F. Sorbara, Schizophrenia and diabetes: epidemiological data.
Eur Psychiatry, 2005. 20 Suppl 4: p. S345-8.
73. Cohen, D., et al., Prevalence of diabetes mellitus in chronic schizophrenic
inpatients in relation to long-term antipsychotic treatment. Eur
Neuropsychopharmacol, 2006. 16(3): p. 187-94.
74. Gianfrancesco, F., et al., Antipsychotic-induced type 2 diabetes: evidence from a
large health plan database. J Clin Psychopharmacol, 2003. 23(4): p. 328-35.
75. Hung, C.F., C.K. Wu, and P.Y. Lin, Diabetes mellitus in patients with schizophrenia
in Taiwan. Prog Neuropsychopharmacol Biol Psychiatry, 2005. 29(4): p. 523-7.
76. Ko, G.T., et al., A low socio-economic status is an additional risk factor for
glucose intolerance in high risk Hong Kong Chinese. Eur J Epidemiol, 2001.
17(3): p. 289-95.
59
77. Chien, I.C., et al., Prevalence of psychiatric disorders among National Health
Insurance enrollees in Taiwan. Psychiatr Serv, 2004. 55(6): p. 691-7.
78. Subramaniam, M., S.A. Chong, and E. Pek, Diabetes mellitus and impaired
glucose tolerance in patients with schizophrenia. Can J Psychiatry, 2003. 48(5):
p. 345-7.
79. Philippe, A., G. Vaiva, and F. Casadebaig, Data on diabetes from the French
cohort study in schizophrenia. Eur Psychiatry, 2005. 20 Suppl 4: p. S340-4.
80. Sernyak, M.J., et al., Association of diabetes mellitus with use of atypical
neuroleptics in the treatment of schizophrenia. Am J Psychiatry, 2002. 159(4): p.
561-6.
81. Lindenmayer, J.P., et al., Changes in glucose and cholesterol levels in patients
with schizophrenia treated with typical or atypical antipsychotics. Am J
Psychiatry, 2003. 160(2): p. 290-6.
82. Baptista, T., Mechanisms of weight gain induced by antipsychotic drugs. J Clin
Psychiatry, 2002. 63(3): p. 245-6.
83. Kroeze, W.K., et al., H1-histamine receptor affinity predicts short-term weight
gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology,
2003. 28(3): p. 519-26.
84. Casey, D.E. and S.H. Zorn, The pharmacology of weight gain with antipsychotics.
J Clin Psychiatry, 2001. 62 Suppl 7: p. 4-10.
85. Brown, S., et al., The unhealthy lifestyle of people with schizophrenia. Psychol
Med, 1999. 29(3): p. 697-701.
86. Curkendall, S.M., et al., Cardiovascular disease in patients with schizophrenia in
Saskatchewan, Canada. J Clin Psychiatry, 2004. 65(5): p. 715-20.
87. Bih, S.H., et al., The treated prevalence and incidence of bipolar disorder among
national health insurance enrollees in Taiwan, 1996-2003. Soc Psychiatry
Psychiatr Epidemiol, 2008. 43(11): p. 860-5.
88. Sacchetti, E., C. Turrina, and P. Valsecchi, Cerebrovascular accidents in elderly
people treated with antipsychotic drugs: a systematic review. Drug Saf, 2010.
33(4): p. 273-88.
89. Newman, S.C. and R.C. Bland, Mortality in a cohort of patients with
schizophrenia: a record linkage study. Can J Psychiatry, 1991. 36(4): p. 239-45.
90. Saha, S., D. Chant, and J. McGrath, A systematic review of mortality in
schizophrenia: is the differential mortality gap worsening over time? Arch Gen
Psychiatry, 2007. 64(10): p. 1123-31.
91. Ruetsch, O., et al., [Psychotropic drugs induced weight gain: a review of the
literature concerning epidemiological data, mechanisms and management].
Encephale, 2005. 31(4 Pt 1): p. 507-16.
60
92. McCreadie, R.G. and G. Scottish Schizophrenia Lifestyle, Diet, smoking and
cardiovascular risk in people with schizophrenia: descriptive study. Br J
Psychiatry, 2003. 183: p. 534-9.
93. Leys, D., et al., Stroke prevention: management of modifiable vascular risk
factors. J Neurol, 2002. 249(5): p. 507-17.
94. Leucht, S., et al., Physical illness and schizophrenia: a review of the literature.
Acta Psychiatr Scand, 2007. 116(5): p. 317-33.
95. Homel, P., D. Casey, and D.B. Allison, Changes in body mass index for individuals
with and without schizophrenia, 1987-1996. Schizophr Res, 2002. 55(3): p. 277-
84.
96. Sweileh, W.M., et al., Diabetes mellitus in patients with schizophrenia in West-
Bank, Palestine. Diabetes Res Clin Pract, 2013. 99(3): p. 351-7.
97. Takayanagi, Y., et al., Diabetes is associated with lower global cognitive function
in schizophrenia. Schizophrenia Research, 2012. 142(1-3): p. 183-187.
98. Alkelai, A., et al., Association of the type 2 diabetes mellitus susceptibility gene,
TCF7L2, with schizophrenia in an Arab-Israeli family sample. PLoS One, 2012.
7(1): p. e29228.
99. Erickson, S.C., et al., New-onset treatment-dependent diabetes mellitus and
hyperlipidemia associated with atypical antipsychotic use in older adults
without schizophrenia or bipolar disorder. J Am Geriatr Soc, 2012. 60(3): p. 474-
9.
100. Schoepf, D., et al., Type-2 diabetes mellitus in schizophrenia: increased
prevalence and major risk factor of excess mortality in a naturalistic 7-year
follow-up. Eur Psychiatry, 2012. 27(1): p. 33-42.
101. Kusumi, I., et al., Screening for diabetes using monitoring guidance in
schizophrenia patients treated with second-generation antipsychotics: A 1-year
follow-up study. Progress in Neuro-Psychopharmacology &; Biological Psychiatry,
2011. 35(8): p. 1922-1926.
102. Liao, C.H., et al., Schizophrenia patients at higher risk of diabetes, hypertension
and hyperlipidemia: A population-based study. Schizophrenia Research, 2011.
126(1-3): p. 110-116.
103. Hsu, J.H., et al., Incidence of diabetes in patients with schizophrenia: a
population-based study. Can J Psychiatry, 2011. 56(1): p. 19-26.
104. Subashini, R., et al., Prevalence of diabetes, obesity, and metabolic syndrome in
subjects with and without schizophrenia (CURES-104). Journal of Postgraduate
Medicine, 2011. 57(4): p. 272-277.
105. Becker, T. and J. Hux, Risk of Acute Complications of Diabetes Among People
With Schizophrenia in Ontario, Canada. Diabetes Care, 2011. 34(2): p. 398-402.
61
106. Tang, C.Y., et al., The effects of hypertension and body mass index on diffusion
tensor imaging in schizophrenia. Schizophr Res, 2011. 130(1-3): p. 94-100.
107. Saddichha, S. and S. Akhtar, Prehypertension, Hypertension and Cardiometabolic
Changes Associated with Antipsychotic Use in Schizophrenia. Basic &; Clinical
Pharmacology &; Toxicology, 2011. 109: p. 33-33.
108. Lev-Ran, S., Y. Le Strat, and B. Le Foll, Impact of hypertension and body mass
index on quality of life in schizophrenia. Am J Psychiatry, 2011. 168(5): p. 552-3.
109. Friedman, J.I., et al., The effects of hypertension and body mass index on
cognition in schizophrenia. Am J Psychiatry, 2010. 167(10): p. 1232-9.
110. Saddichha, S., N. Manjunatha, and S. Akhtar, Obesity, Diabetes and
Hypertension Associated with Antipsychotic Use in Drug Naive Schizophrenia.
Australian and New Zealand Journal of Psychiatry, 2010. 44: p. A12-A13.
111. Piette, J.D., et al., Differential medication adherence among patients with
schizophrenia and comorbid diabetes and hypertension. Psychiatric Services,
2007. 58(2): p. 207-212.
112. Johannessen, L., et al., Increased risk of hypertension in patients with bipolar
disorder and patients with anxiety compared to background population and
patients with schizophrenia. J Affect Disord, 2006. 95(1-3): p. 13-7.
113. Nasrallah, H.A., et al., Low rates of treatment for hypertension, dyslipidemia and
diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at
baseline. Schizophrenia Research, 2006. 86(1-3): p. 15-22.
114. Lund, B.C., et al., Clozapine use in patients with schizophrenia and the risk of
diabetes, hyperlipidemia, and hypertension - A claims-based approach. Archives
of General Psychiatry, 2001. 58(12): p. 1172-1176.
115. Hsu, J.H., et al., Hyperlipidemia in patients with schizophrenia: a national
population-based study. Gen Hosp Psychiatry, 2012. 34(4): p. 360-7.
116. Erickson, S.C., et al., New-Onset Treatment-Dependent Diabetes Mellitus and
Hyperlipidemia Associated with Atypical Antipsychotic Use in Older Adults
without Schizophrenia or Bipolar Disorder. Journal of the American Geriatrics
Society, 2012. 60(3): p. 474-479.
117. Darba, J., et al., A simulation model to estimate 10-year risk of coronary heart
disease events in patients with schizophrenia spectrum disorders treated with
second-generation antipsychotic drugs. Annals of Clinical Psychiatry, 2013.
25(1): p. 17-26.
118. Birkhofer, A., et al., The deceleration capacity - a new measure of heart rate
variability evaluated in patients with schizophrenia and antipsychotic
treatment. European Psychiatry, 2013. 28(2): p. 81-86.
119. Kim, J.H., et al., Effects of Clozapine on Heart Rate Dynamics and Their
62
Relationship With Therapeutic Response in Treatment-Resistant Schizophrenia.
Journal of Clinical Psychopharmacology, 2013. 33(1): p. 69-73.
120. Lee, K., et al., Heart Rate Variability and Metabolic Syndrome in Hospitalized
Patients with Schizophrenia. Journal of Korean Academy of Nursing, 2011.
41(6): p. 788-794.
121. Arango, C., et al., Psychopathology, coronary heart disease and metabolic
syndrome in schizophrenia spectrum patients with deficit versus non-deficit
schizophrenia: Findings from the CLAMORS study. European
Neuropsychopharmacology, 2011. 21(12): p. 867-875.
122. Rachow, T., et al., Nonlinear relationship between electrodermal activity and
heart rate variability in patients with acute schizophrenia. Psychophysiology,
2011. 48(10): p. 1323-1332.
123. Kim, J.H., J.H. Ann, and J. Lee, Relationship between heart rate variability and
the severity of psychotic symptoms in schizophrenia. Acta Neuropsychiatrica,
2011. 23(4): p. 161-166.
124. Laursen, T.M. and M. Nordentoft, Heart disease treatment and mortality in
schizophrenia and bipolar disorder - Changes in the danish population between
1994 and 2006. Journal of Psychiatric Research, 2011. 45(1): p. 29-35.
125. Henry, B.L., et al., Heart rate variability in bipolar mania and schizophrenia. J
Psychiatr Res, 2010. 44(3): p. 168-76.
126. Barnett, A.H., et al., UK cost-consequence analysis of aripiprazole in
schizophrenia: diabetes and coronary heart disease risk projections (STAR
study). Eur Arch Psychiatry Clin Neurosci, 2009. 259(4): p. 239-47.
127. Nurjono, M. and J. Lee, Predictive utility of blood pressure, waist circumference
and body mass index for metabolic syndrome in patients with schizophrenia in
Singapore. Early Interv Psychiatry, 2013. 7(2): p. 205-9.
128. Yu, W., et al., CNR1 gene and risk of the metabolic syndrome in patients with
schizophrenia. J Clin Psychopharmacol, 2013. 33(2): p. 186-92.
129. Suzuki, Y., et al., Low prevalence of metabolic syndrome and its prediction in
Japanese inpatients with schizophrenia. Hum Psychopharmacol, 2013. 28(2): p.
188-91.
130. Mitchell, A.J., et al., Is the Prevalence of Metabolic Syndrome and Metabolic
Abnormalities Increased in Early Schizophrenia? A Comparative Meta-Analysis
of First Episode, Untreated and Treated Patients. Schizophrenia Bulletin, 2013.
39(2): p. 295-305.
131. Lee, N.Y., et al., The prevalence of metabolic syndrome and its association with
alanine aminotransferase in clozapine-treated Korean patients with
schizophrenia. International Clinical Psychopharmacology, 2013. 28(2): p. 71-79.
63
132. Grover, S., et al., Prevalence of metabolic syndrome in patients with
schizophrenia in India. Psychiatry Research, 2012. 200(2-3): p. 1035-1037.
133. Sweileh, W.M., et al., Prevalence of metabolic syndrome among patients with
Schizophrenia in Palestine. Bmc Psychiatry, 2012. 12.
134. Na, K.S., et al., Relationship between inflammation and metabolic syndrome
following treatment with paliperidone for schizophrenia. Progress in Neuro-
Psychopharmacology &; Biological Psychiatry, 2012. 39(2): p. 295-300.
135. Said, M.A., et al., Metabolic syndrome and cardiovascular risk among patients
with schizophrenia receiving antipsychotics in Malaysia. Singapore Medical
Journal, 2012. 53(12): p. 801-807.
136. Lindenmayer, J.P., et al., Relationship between metabolic syndrome and
cognition in patients with schizophrenia. Schizophrenia Research, 2012. 142(1-
3): p. 171-176.
137. Zhang, L., et al., Prevalence of chronic kidney disease in China: a cross-sectional
survey. Lancet, 2012. 379(9818): p. 815-22.
138. Baigent, C., et al., The effects of lowering LDL cholesterol with simvastatin plus
ezetimibe in patients with chronic kidney disease (Study of Heart and Renal
Protection): a randomised placebo-controlled trial. Lancet, 2011. 377(9784): p.
2181-92.
139. James, M.T., et al., Glomerular filtration rate, proteinuria, and the incidence and
consequences of acute kidney injury: a cohort study. Lancet, 2010. 376(9758): p.
2096-103.
140. Chronic Kidney Disease Prognosis, C., et al., Association of estimated glomerular
filtration rate and albuminuria with all-cause and cardiovascular mortality in
general population cohorts: a collaborative meta-analysis. Lancet, 2010.
375(9731): p. 2073-81.
141. Meguid El Nahas, A. and A.K. Bello, Chronic kidney disease: the global
challenge. Lancet, 2005. 365(9456): p. 331-40.
142. Phrommintikul, A., et al., Mortality and target haemoglobin concentrations in
anaemic patients with chronic kidney disease treated with erythropoietin: a
meta-analysis. Lancet, 2007. 369(9559): p. 381-8.
143. Wen, C.P., et al., All-cause mortality attributable to chronic kidney disease: a
prospective cohort study based on 462 293 adults in Taiwan. Lancet, 2008.
371(9631): p. 2173-82.
144. James, M.T., B.R. Hemmelgarn, and M. Tonelli, Early recognition and prevention
of chronic kidney disease. Lancet, 2010. 375(9722): p. 1296-309.
145. Nankivell, B.J. and D.R. Kuypers, Diagnosis and prevention of chronic kidney
allograft loss. Lancet, 2011. 378(9800): p. 1428-37.
64
146. Levey, A.S. and J. Coresh, Chronic kidney disease. Lancet, 2012. 379(9811): p.
165-80.
147. Schraffenberger, L.A., New ICD-9-CM diagnostic codes for fiscal year 2008. J
AHIMA, 2007. 78(8): p. 84-7.
148. Lai, S.W., et al., Risk of hepatocellular carcinoma in diabetic patients and risk
reduction associated with anti-diabetic therapy: a population-based cohort
study. Am J Gastroenterol, 2012. 107(1): p. 46-52.
149. Kuo, H.W., et al., Epidemiological features of CKD in Taiwan. Am J Kidney Dis,
2007. 49(1): p. 46-55.
150. Chen, Y.F., et al., Retinitis pigmentosa reduces the risk of proliferative diabetic
retinopathy: a nationwide population-based cohort study. PLoS One, 2012. 7(9):
p. e45189.
151. Woo, J.G., et al., Obesity identified by discharge ICD-9 codes underestimates the
true prevalence of obesity in hospitalized children. J Pediatr, 2009. 154(3): p.
327-31.
152. Lai, E.C., et al., Effectiveness of sulpiride in adult patients with schizophrenia.
Schizophr Bull, 2013. 39(3): p. 673-83.
153. Arana, G.W., An overview of side effects caused by typical antipsychotics. J Clin
Psychiatry, 2000. 61 Suppl 8: p. 5-11; discussion 12-3.
154. McIntyre, R.S., Antipsychotic drugs and diabetes. CMAJ, 2003. 168(6): p. 673.
155. Melkersson, K. and A.L. Hulting, [Antipsychotic drugs can affect hormone
balance. Weight gain, blood lipid disturbances and diabetes are important].
Lakartidningen, 2001. 98(48): p. 5462-4, 5467-9.
156. Spoelstra, J.A., et al., Antipsychotic drugs may worsen metabolic control in type
2 diabetes mellitus. J Clin Psychiatry, 2004. 65(5): p. 674-8.
157. Stip, E., et al., [Antipsychotic drugs. Risk factors for diabetes]. Presse Med, 2003.
32(34): p. 1612-7.
158. Isaac, M.T. and M.B. Isaac, Consensus development conference on antipsychotic
drugs and obesity and diabetes: response to consensus statement. Diabetes
Care, 2004. 27(8): p. 2088; author reply 2089-90.
159. Lean, M.E. and F.G. Pajonk, Patients on atypical antipsychotic drugs: another
high-risk group for type 2 diabetes. Diabetes Care, 2003. 26(5): p. 1597-605.
160. Hardy, T. and A. Breier, Patients on atypical antipsychotic drugs: another high-
risk group for type 2 diabetes: response to Lean and Pajonk. Diabetes Care,
2003. 26(11): p. 3200-1.
|